# Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial

> **NCT01692496** · PHASE2 · COMPLETED · sponsor: **Grupo Espanol de Investigacion en Sarcomas** · enrollment: 52 (actual)

## Conditions studied

- Advanced and / or Metastatic Liposarcoma

## Interventions

- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT01692496
- **Lead sponsor:** Grupo Espanol de Investigacion en Sarcomas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-29
- **Primary completion:** 2018-03
- **Final completion:** 2018-03-02
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2020-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01692496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01692496, "Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01692496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*